40 results about "Phosphatidylethanolamine" patented technology

The application provides a topical traditional Chinese medicine composition for treating vulvar leukoplakia and a preparation method thereof. The composition is composed of traditional Chinese medicinal materials such as angelica, cortex psoraleae and barks of dictamnus dasycarpus, and a penetration enhancer, an activating agent and a moisturizing agent. The penetration enhancer is composed of soybean lecithin, phosphatidylethanolamine and cholesterol, the activating agent is sodium cholate, sodium deoxycholate and sodium taurocholate, and the moisturizing agent is eucalyptus oil. The drugs are compatible to exert the effects of clearing heat and drying dampness, cooling blood and nourishing yin, activating blood and resolving stasis, warming yang and dispelling cold and supporting healthy qi and tonifying the body resistance. The traditional Chinese medicine composition is prepared through supercritical extraction, micronization treatment, solution preparation and intermittent ultrasonic homogenization. The traditional Chinese medicinal materials are used for treating the etiology, pathogenesis and symptoms of vulvar leukoplakia, the penetration enhancer reduces the skin barrier function, the activating agent enhances the drug activity and permeability, and the moisturizing agent maintains the skin moisture and assists in anti-inflammation. The clinical application effectively relieves the symptoms of patients with vulvar leukoplakia, improves the pathological state of local skin and improves the treatment effect, thereby providing a new effective option for the treatment of vulvar leukoplakia.

The invention discloses a functional lipid compound for nano-liposome wrapping and a preparation method, and relates to the technical field of functional lipid compounds, the functional lipid compound comprises (a) a polyphenol-lipid covalent conjugate which is composed of a polyphenol active unit selected from curcumin, dihydroquercetin or derivatives thereof, and (b) a lipid covalent conjugate which is composed of a polyphenols active unit selected from curcumin, dihydroquercetin or derivatives thereof and a polyphenols active unit selected from curcumin, dihydroquercetin or derivatives thereof; the conjugate is covalently linked to a phosphatidyl ethanolamine or cholesterol skeleton through a cleavable linking group, and the conjugate can be integrated into a nano-liposome membrane and has the functions of structural support and biological activity; (b) a microenvironment-responsive functional phospholipid, which is a phospholipid derivative having a functional group responsive to an inflammatory microenvironment specific stimulus modified on a hydrophilic head group or a hydrophobic chain of a phospholipid molecule, the specific stimulus being selected from local pH < = 6.5, reactive oxygen species (ROS) concentration > = 10 [mu] M or matrix metalloproteinase MMP-2 / 9 overexpression; and (c) a bionic exosome membrane lipid component, wherein the bionic exosome membrane lipid component comprises sphingosine-based glycolipid or sulfated cholesterol separated from the plant-derived exosome.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

The present invention relates to ophthalmic compositions comprising at least one substance of at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, megamine and derivatives thereof, and / or the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particularly preferred are choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g. Lecithin having a phosphatidylcholine content of > = 80% by weight, e.g. Soybean lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-alpha-glycerophosphorylcholine, phosphatidylcholine, phosphatidylethanolamine.

A reagent for measuring activated partial thromboplastin time, the reagent comprising phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE), wherein the ratio (PS / PC) of the concentration of the PS to the concentration of the PC is 0.26-2.00, and the concentration of the PS is 14-60 µg / mL.

This invention belongs to the fields of pharmaceutical biotechnology and clinical medicine, specifically relating to a peripheral blood phosphatidylethanolamine biomarker for the objective diagnosis of depression, and particularly to the application of phosphatidylethanolamine (PE) (18:1 / 18:3) in the diagnosis and risk assessment of depression. This invention provides an objective diagnostic method based on peripheral blood, overcoming the inherent subjectivity of traditional psychiatric diagnoses, and can be used for the auxiliary diagnosis, early screening, and risk assessment of depression.

The embodiments disclosed herein relate to a liposomal composition for sustained release of an active ingredient. In various implementations, the liposomal composition may have a first liposomal core of Phosphatidylcholine (PC), phosphatidylethanolamine (PE), or phosphatidylserine (PS) and the active ingredient dispersed within the first liposomal core. A second core may surround the first liposomal core, with the second core optionally containing one or more polypeptide and a polysaccharide.

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.

The present invention relates to a method of reducing the phospholipid content in an oil or fat composition and polypeptides having PI-specific phospholipase C activity as well as polypeptides having PC, PE-specific phospholipase C activity and combinations thereof capable of catalyzing this reduction. The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

The invention relates to the technical field of assay and inspection, in particular to a method for detecting ceramide and phosphatidyl ethanolamine in neonatal dried blood spots, and the preparation method comprises the following steps: S1, drawing a standard curve equation: preparing an internal standard extract; preparing a mixed standard solution; preparing standard substance solutions with a series of concentrations; adding the internal standard extraction liquid into the standard substance solution, carrying out pretreatment, and carrying out HPLC-MS / MS detection to respectively obtain a ceramide standard curve and a phosphatidyl ethanolamine standard curve; and S2, detecting the contents of ceramide and phosphatidyl ethanolamine in the dried blood spot to be detected, namely adding the internal standard extract into the dried blood spot to be detected, performing pretreatment, performing HPLC-MS / MS detection, and obtaining the contents of ceramide and phosphatidyl ethanolamine according to a ceramide standard curve and a phosphatidyl ethanolamine standard curve respectively. The detection method provided by the embodiment of the invention has the characteristics of high accuracy, good sensitivity, stability and simplicity and convenience in operation.

The invention discloses a phospholipid hydrophilic chromatographic separation and evaporative light scattering detection method suitable for liquid milk, milk powder and milk source raw materials. The method comprises the following steps: preparing a sample solution from a sample to be detected; extracting the sample solution by using a solution of chloroform and methanol to obtain subnatant as extract liquor; adding a saturated salt solution into the extract liquor for chromatographic purification, and taking separated lower clear liquid as purified liquid; preparing the purified liquid into a sample introduction liquid; and determining the phospholipid content in the sample injection solution by using a liquid chromatography-evaporative light scattering detector. In the detection method, a sample solution is extracted by using a solution of chloroform and methanol, and a saturated salt solution is added into an extraction solution for chromatographic purification, so that chromatographic peaks are not interfered, and various phospholipids in food can be accurately measured at the same time; the method can be used for simultaneously determining phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidylserine and phosphatidylinositol in food, and has the advantages of simplicity, rapidness, accuracy, low detection limit and high sensitivity.

A persistent encapsulation structure capable of preventing the degradation of bioactive substances, which encapsulation structure comprises a variety of encapsulation structure bodies (10), characterized by that the respective encapsulation structure body (10) has a polysaccharide structure (11) by which a plurality of bioactive substances (12) are encapsulated, wherein the bioactive substance (12) is selected from a group consisting of a bioactive fatty substance (121) and a bioactive non-fatty substance (122); that the polysaccharide structure (11) comprises at least one polysaccharide, wherein the at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed and finally atomized dried, such that the polysaccharide structure (11) forms branched polysaccharides and linear polysaccharides which form a multitude of network structures; that the bioactive fatty substance (121) is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances; and that the bioactive nonfatty substance (122) is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives.

The present invention relates to ophthalmic compositions comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, particularly varenicline, mecamillamine, and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts thereof, and choline-containing phospholipids, salts and derivatives thereof. Of these, choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g., lecithin with a phosphatidylcholine content of 80% by weight or more, e.g., soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine are particularly preferred.

The application discloses a plasma metabolic marker composition and a screening method and application thereof, and relates to the technical field of biomedicine. The plasma metabolic marker composition comprises glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-formic acid and phosphatidylethanolamine 36:2p. The metabolic marker composition is significantly different in different cancer types, can distinguish different cancer types of cancer patients, and realizes the detection of pan-cancer. The metabolic marker composition is non-invasive and minimally invasive when used for the detection of pan-cancer, is more suitable for the screening and detection of a large number of ordinary people, has high sensitivity and specificity, is more suitable for the early screening of cancer, and is helpful for the early screening, early diagnosis and early treatment of cancer, and is helpful for improving the survival rate and cure rate of cancer patients.

The strain BS-14 can convert the nutrients in the solid culture into nutrients absorbed and utilized by the bacillus subtilis, and the microenvironment generated by the fermentation of the strain BS-14 is also beneficial to promote the fermentation of MQ013-26, so that the enzyme activity concentration of the natto kinase is further improved. The strain BS-14 can further decompose phospholipid substances (phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol) and fat, so that the spoilage odor of the freeze-dried powder can be further improved, and the shelf life can be prolonged. The strain BS-14 can further generate active peptides against pathogenic microorganisms, and has significant bacteriostatic activity, so that the quality safety of the freeze-dried powder is improved.

The invention discloses a method for identifying a sea cucumber producing area based on combination of lipidomics and machine learning, which realizes accurate identification of the sea cucumber producing area by acquiring lipidomics data and screening and identifying markers and combining a machine learning model and interpretability analysis. According to the method, triglyceride, phosphatidic acid and phosphatidyl ethanolamine are obtained through screening as lipid markers, Dalian local sea cucumber and Fujian northern sea cucumber and southern sea cucumber can be accurately distinguished, the method has the advantages of being high in accuracy, high in interpretability and good in universality, and the method can be used for sea cucumber production place identification and supervision sampling inspection; and an effective technical means is provided for aquatic product producing area traceability and identification.

The invention discloses a novel oil-soluble micelle preparation. The component A comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, cardiolipin, cephalin and dipalmitoyl phosphatidylcholine, and the component B comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, phosphatidylcholine, cephalin and dipalmitoyl phosphatidylcholine; one or more of dipalmitoyl phosphatidyl ethanolamine and dipalmitoyl phosphatidyl ethanolamine; the component B comprises a component B1 and a component B2, and the component B1 comprises one or more of phytosterol, cholesterol, ergosterol, protopanoxadiol, protopanaxatriol, ganoderic acid, phytol, isophytol, retinol, andrographolide, paclitaxel, artemisinin and bisabolol; and the component B2 is prepared from one or more of 1, 2-hexanediol, ethylhexylglycerin, cyclohexyl glycerin, absolute ethyl alcohol and isosorbide dimethyl ether. The key point of the invention is to provide a low-cost formula and a low-cost preparation method for preparing the oil-soluble micelle preparation.

An APTT detection reagent, a preparation method and application thereof. The APTT detection reagent comprises an R1 reagent and an R2 reagent, the R1 reagent comprises a phospholipid mixture selected from any two of phosphatidylserine, phosphatidylethanolamine and phosphatidylcholine; and the concentration of the phospholipid mixture ranges from 0.1 g / L to 1 g / L. The APTT detection reagent improves the sensitivity of the APTT reagent to LA patients and the APTT detection has improved thermal stability.

The invention relates to a rapid excavation technology for phosphatidylcholine type DHA / EPA and phosphatidyl ethanolamine type DHA / EPA based on mass spectrum dual-mode multiple characteristics, and belongs to the field of research on chemical components of aquatic products. Phospholipid-type EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) components have wide pharmacological activity and good bioavailability, mainly exist in aquatic products such as fishes, shrimps, shellfish and algae, are important nutrient elements which are indispensable to human bodies but cannot be synthesized by themselves, have indispensable effects on human health, and can be used for preparing health-care food. Wherein phosphatidylcholine type DHA / EPA (PCEPA / DHA) and phosphatidyl ethanolamine type DHA / EPA (PEEPA / DHA) are reported at most. According to the method, the krill oil and the fish oil are analyzed by adopting a liquid chromatography-tandem high-resolution mass spectrometry technology, a plurality of mass spectrometry characteristics of positive and negative ion dual modes and python programming are fused to construct a rapid mining algorithm, PCEPA / DHA and PEEPA / DHA in the krill oil and the fish oil are discovered, and an effective technical support is provided for deep discovery, development and utilization of high-value phospholipid DHA and EPA in the krill oil and the fish oil.

A process for degumming a vegetable oil comprising the steps of: a) providing a vegetable oil containing a quantity of phospholipids, b) contacting the oil with one or more phospholipases in presence of water, c) separating the reaction mixture of step b) into a light phase and a heavy phase, and d) producing a degummed vegetable oil, wherein the phospholipase has at least 75 percent sequence identity to SEQ ID NO: 1, wherein more than 75% or 85% or 90% of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) is hydrolyzed, and more than 25% or 35% or 50% of phosphatidic acid (PA) is hydrolyzed and wherein the process is carried out at a temperature of 70°C or above.

The invention belongs to the technical field of biological medicines, and discloses a cardiac function enhancer and application thereof. The active ingredient of the cardiac function enhancer is polyunsaturated phosphatidyl ethanolamine or 3-denitrified adenosine. The polyunsaturated phosphatidyl ethanolamine can be directly used as a key lipid for enhancing the cardiac function. And 2, 3-denitrified adenosine competitively inhibits phosphatidyl ethanolamine methyltransferase to reduce the conversion of phosphatidyl ethanolamine to phosphatidylcholine, so that the level of endogenous polyunsaturated phosphatidyl ethanolamine is improved, and the same effect is indirectly achieved. The invention provides application of the active ingredients in preparation of medicines or nutritional supplements for treating heart diseases, preventing and inhibiting cardiac hypertrophy and improving heart functions.

The invention relates to the technical field of biological medicine, and provides a plasma metabolite-based ALC and AH noninvasive differential diagnosis model, which is characterized in that five plasma key metabolites are taken as core indexes, and a probability calculation model is constructed through a logistic regression algorithm; the five kinds of plasma key metabolites are respectively an Ab-fubinaca metabolite 3, isocitric acid, N-docosahexaenoyl cysteine, gluconic acid-delta-lactone, and 1-palmitoyl-2-linoleyl phosphatidylethanolamine. The invention further provides a construction method and application of the model. According to the method, five key plasma metabolites with remarkable difference between AH and ALC are screened, modeling is carried out in combination with a logistic regression algorithm, or a multi-parameter model is constructed by further integrating prothrombin time, so that accurate non-invasive efficient identification of AH and ALC is realized.

The application discloses a preparation method of cherimoya leaf extract and belongs to the technical field of natural medicine extraction and preparation. The conventional preparation method of the cherimoya leaf extract in the prior art has limited bioavailability of the extract, and lacks a systematic method for effectively enriching specific active components of the extract and stably encapsulating the specific active components in a suitable delivery system. The preparation method provided by the application comprises the following steps: crushing dried cherimoya leaves, refluxing and extracting the dried cherimoya leaves with an ethanol aqueous solution, and concentrating the extract; adding ethyl acetate to the concentrated solution to perform extraction; mixing the obtained ethyl acetate extraction phase with a phospholipid aqueous dispersion liquid composed of phosphatidylcholine and phosphatidylethanolamine in a specific ratio; performing high-pressure homogenization treatment to obtain a nanoliposome suspension liquid; and finally performing spray drying to obtain an extract powder. The extract prepared by the method can be used for preparing a medicine for treating type 2 diabetes.

Extracellular vesicles (PDEVs) for reaching the blood-brain barrier characterized by: be obtained from oranges from organic farming and to contain within the lipid membrane a ratio between the concentration of Phosphatidylethanolamine (PE) and the concentration of Phosphatidic Acid (PA) between 8 and 15.

This invention, through lipidomics and clinical sample validation, found that prospective follow-up of pre-pregnancy serum samples from women with a history of recurrent pregnancy loss (RPL) revealed that the pre-pregnancy serum levels of phosphatidylinositol PI (18:1 / 18:1) (i.e., PI 36:2), phosphatidylcholine (29:0-6:0) (i.e., PC 35:0), phosphatidylethanolamine (18:1p-18:2) (i.e., PE 36:3p), triglycerides (28:1-10:4-11:2) (i.e., TG 49:7), triglycerides (14:0-18:2-20:5) (i.e., TG 52:7), and wax esters (22:1) (i.e., WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. This confirms that the pre-pregnancy serum levels of these six lipids (PI 36:2, PC 35:0, PE 36:3p, TG 49:7, TG 52:7, WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. Decreased levels of 22:1 lipids were significantly associated with the risk of miscarriage in subsequent pregnancies. The area under the curve (AUC) of the predictive model constructed by combining six lipids reached 0.85, demonstrating good predictive efficacy. Based on these findings, this lipid combination can serve as a reliable predictor of miscarriage risk in subsequent pregnancies in RPL patients and can be used to develop diagnostic reagents or kits for preconception risk screening.

The application discloses a Tet1 modified cationic liposome for loading siBACE1, a preparation method and application thereof, and belongs to the technical field of biological medicines. The application solves the problem of limited treatment effect of siBACE1 in treating Alzheimer's disease in the prior art. The application comprises siBACE1, the siBACE1 is externally coated with a lipid composition, and the lipid composition is modified with a Tet1 peptide; the lipid composition is composed of 1,2-dioleoyl-3-trimethylammonium propane, dioleoylphosphatidylethanolamine, cholesterol and distearoylphosphatidylethanolamine-polyethylene glycol 2000. The Tet1 modified cationic liposome for loading siBACE1 can deliver siBACE1 to an action site, improve the action effect, and effectively treat Alzheimer's disease.

The present invention provides ultrasound-responsive liposome nanoparticles and a preparation method and use thereof. The liposome nanoparticles include dimyristoylphosphatidylcholine, 1,2-dioleoyl-3-trimethyl ammonium-propane, distearoylphosphatidylethanolamine-polyethylene glycol, a sonosensitizer, an antibiotic, and perfluoropentane. The liposome nanoparticles are used for the treatment of bacterial biofilm infections. The preparation method involves preparing a liposome film.

The present application relates to the biomedical technology field, especially to an immune regulation chiral material and its preparation method and application, the immune regulation chiral material is self-assembled by immune active component and delivery carrier.Immune active component is selected from chiral peptide modified distearoyl phosphatidylethanolamine-polyethylene glycol, and the chiral peptide is connected by 6-10 D-alanine monomers by amide bond.The material can realize precise targeting of target cells by specific stereoscopic recognition of chiral peptide and immune cell surface receptors, and reduce non-specific effects on normal tissues;Delivery carrier represented by lipid nanoparticles can effectively protect chiral peptide from in vivo enzymolysis, improve its circulating stability, and natural carriers such as exosomes can enhance the biocompatibility and tissue penetration of the material, providing a new strategy for immunotherapy of diseases such as tumors, and being expected to be applied to clinical treatment as a new immunotherapy drug.

This invention relates to the field of fluorescent probe technology, specifically disclosing a nanoprobe for detecting hydroxyl radicals in living cells, comprising a core and a shell layer. The shell layer is distearylphosphatidylethanolamine-polyethylene glycol 2000, and the core is 4,7-bis(4-(methylthio)phenyl)benzo[c][1,2,5]thiadiazole (BT-S), the structural formula of which is shown in formula (I). This invention also provides a method for preparing this nanoprobe and its applications. The nanoprobe of this invention has the advantages of simple preparation process, stable performance, high detection sensitivity, good specificity, and excellent biocompatibility.

The invention discloses an intelligent drug co-delivery liposome for targeted therapy of Alzheimer's disease as well as a preparation method and application of the intelligent drug co-delivery liposome. The invention relates to a brain-targeted peptide-responsive liposome, which is composed of a brain-targeted peptide-grafted maleeimine-polyethylene glycol-phosphatidylethanolamine (DSPE-PEG2000-ANG2), an ROS (reactive oxygen species) responsive lipid DSPE-TK-PEG2000, hydrogenated soybean phospholipid (HSPC), cholesterol (Chol), and a GSK-3beta inhibitor 7BIO and dipalmitoyl phosphatidylserine (DPPS), wherein the GSK-3beta inhibitor 7BIO and the dipalmitoyl phosphatidylserine (DPPS) are used as drugs. According to the present invention, the intracerebral delivery efficiency of 7BIO is significantly improved, the acidification disorder of lysosome in damaged neurons is improved while the damaged lysosome membrane is recovered, the aggregation deposition of A beta is inhibited, the systemic toxicity is reduced, and the safe and efficient new strategy is provided for the treatment of Alzheimer's disease.